Board

Jörgen Wennberg
Chairman of the Board since 2022

Born:

1952

Shares in SpectraCure AB:

1 349 126 shares
(incl. Related *)

Jörgen has a marketing diploma and has worked for over 30 years within the ICA Group. He is a former CEO of ICA Banken and has several years of experience in board work. Jörgen has previously been a member of ICA AB Group Management team and a board member of the Swedish Bankers’ Association.
Jörgen Wennberg is independent of the Company and the owners.
Tomas Kramar
Board member since 2022
Born:

1954

Shares in SpectraCure AB:

25 000 shares

Tomas has a Master of Science in Chemical Engineering from Lund University. He has over 40 years of experience from the life science industry and has previously worked as CEO of Siemens Healthineers, as well as CEO of Siemens Healthcare Diagnostics. Tomas has also worked at Abbott Laboratories, Becton Dickinson och Hoffmann La Roche. Tomas is chairman of Kramar Group AB and the Percy Falk Cancer Foundation. He is also a board member of Nanologica AB, Gentian A / S, Corsmed AB, Lundonia Biotech AB and CytaCoat AB.
Tomas Kramar is independent of the Company and the owners.
Interview with Tomas
Masoud Khayyami
Board member since 2022
Born:

1963

Shares in SpectraCure AB:

11 116 402 shares (incl. Related  and via companies)

Masoud has a PhD in technical chemistry and has solid experience from research in medical technology and biotechnology. He has previously been CEO of SpectraCure AB. Masoud has entrepreneurial experience in companies such as Lumito AB, Gasporox AB and Prolight Diagnostics AB. Today, Masoud works as CEO of Cardeon AB.
Masoud Khayyami is not independent of the Company and the owners.
Jesper Freij
Board member since 2022
Born

1971

Shares in SpectraCure AB:

4 500 shares

Jesper holds a Master’s degree in Business Administration from the School of Economics at Lund University. He has worked in the pharmaceutical industry in the Nordic region since 1998, of which 20 years in various management positions.  Jesper has also worked at Novo Nordisk and Novartis. At Novartis, and its former subsidiary Alcon, he worked for eight years as Nordic Franchise Head Ophthalmology, with responsibility for their eye drugs. There, Jesper had, among other things, responsibility for Visudyne. Today, Jesper works as a consultant in life science with a focus on launch preparations, marketing and leadership.
Jesper Freij is independent of the Company and the owners.

Stefan Andersson-Engels

Board member since 2025

Born:

1960

Shares in SpectraCure AB:

0 shares

Stefan Andersson-Engels holds a Master of Science in Engineering Physics from Lund University and a PhD in Medical Laser Physics from the same university. He has been a member of the board of Lumito AB (publ) since 2011. Stefan Andersson-Engels is currently the Director of Biophotonics at the Tyndall National Institute in Ireland, Deputy Director of the Photonics Centre IPIC in Cork, and Professor of Physics at University College Cork, Ireland. Prior to his current role, he was a Professor of Physics at Lund University until 2016. Since then, he has been responsible for leading the biophotonics research activities at Tyndall, overseeing a team of approximately 40 researchers. Stefan Andersson-Engels has received several awards, including the Erna Ebeling Prize from the Swedish Society for Medical Engineering and Physics (2003), and he was a shortlisted candidate for the professorship in Biomedical Physics at the Royal Institute of Technology (KTH) in 1996. He is co-author of over 200 scientific articles published in peer-reviewed journals.

Stefan Andersson-Engels is independent of the Company and the owners.

Patrik Ringblom

Board member since 2025

Born:

1964

Shares in SpectraCure AB:

0 shares

Extensive experience gained from having spent the majority of their career at Johnson & Johnson (J&J). Started as a sales representative in Sweden and subsequently advanced to global leadership roles. In 2012, appointed Vice President of the Global Strategy Organization, Oncology, in the United States, and for 10 years was part of the dedicated team that developed and commercialized 10 transformative oncology drugs, including Darzalex, Imbruvica, and Carvykti. In 2022, appointed Vice President, Rare Disease Novel Therapeutics & Alliance, with primary responsibility for driving external innovation of assets in both early and late stages. Since 2023, serving as VP, Head of Strategy & US Lead at Galapagos, leading the establishment and expansion of Galapagos’ presence in the U.S., attracting top talent, and increasing value creation in collaboration with strategic partners.

Patrik Ringblom is independent of the Company and the owners.

Definition
Spouse/spouse or person who is regarded as equal to spouse/spouse as a person with whom the insider has entered into partnership and cohabitation.
Children that the person in the leading position has custody of. A relative who has shared the same household for at least one year at the date the transaction took place, for example, adult children.

Legal entities
a) whose management information is performed by a person in a senior position or physically related person; or
b) directly or indirectly controlled by such person;
c) prepared in favor of such person; or
d) whose financial interests mainly correspond to the interest of such person.

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope